Breaking News: Cellular Biomedicine Group ( NASDAQ: $CBMG) and #GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies

Breaking News: Cellular Biomedicine Group ( NASDAQ:  $CBMG) and  #GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies

SHANGHAI, China and CUPERTINO, Calif., April 10, 2017-- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases and GE Healthcare Life Sciences China, today announced that they have established a strategic research collaboration to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.  In connection with the collaboration, a joint laboratory within CBMG`s new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.

CBMG and GE Healthcare Life Sciences China plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG`s GMP facilities in Shanghai, Wuxi and Beijing.  The co-development activity will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens and to minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.

This partnership combines CBMG`s scientific expertise in the manufacturing of CAR-T and stem cell production in China and GE Healthcare`s renowned expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry.

Recently, CBMG announced that its new Zhangjiang facility, together with an expanded Wuxi, and Beijing GMP-facilities, will have a combined 70,000 square feet for development and production. This will enable CBMG to conduct simultaneous clinical trials for multiple CAR-T and stem cell product candidates. At full production volumes, these facilities could support the treatment of up to 10,000 cancer patients and 10,000 knee osteoarthritis patients per year.

"GE Healthcare`s selection of our facility to serve as their showcase site in China, credits our GMP stature and capabilities. Our team of scientists has spent years refining our manufacturing process to become one of the very few cell therapy companies with fully in-house integrated chemistry, manufacturing, and controls (CMC) processes for clinical grade CAR-T cells, plasmid and viral vectors bank production. We understand that one of the impending barriers to adoption of immuno-oncology and stem cell therapies is the logistics in manufacturing and we look to take an expanded role both domestically and potentially globally.  We are pleased to be in a strategic partnership with GE Healthcare and look forward to showcasing our facilities and the mutual benefit this joint laboratory will bring," commented Tony Liu, Chief Executive Officer, CBMG.

"Cell therapy as an industry continues to refine and evolve in China with vast potential to change the ways various diseases are treated.  GE continues investing in technologies and services aimed at the thriving cell therapy industry with a firm commitment of making these promising therapies accessible through successful industrialization. We are pleased to partner with CBMG, a leader in CAR-T and stem cell development in China and to take advantage of their excellent CMC cell production capabilities. Collaboration with ambitious partners like CBMG who share our vision is necessary for advancing innovation and delivering comprehensive manufacturing solutions for cell and regenerative medicines," said Li Qing, General Manager, GE Healthcare Life Sciences, Greater China.

Read this release in full at http://www.investorideas.com/news/2017/biotech/04131CBMG.asp

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. (CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG`s "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. To learn more about CBMG, please visit www.cellbiomedgroup.com.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.  GE (GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Forward-Looking Statements

This press release contains forward-looking statements-including descriptions of plans, strategies, trends, specific activities, investments and other non-historical facts-as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMG`s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," "continue" or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Contacts:

Sarah Kelly

Director of Corporate Communications, CBMG

+1 408-973-7884

sarah.kelly@cellbiomedgroup.com

Vivian Chen

Managing Director Investor Relations, Citigate Dewe Rogerson

+1 347 481-3711

vivian.chen@citigatedr.com

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Energy, Mining, Biotech, Sports and Automotive Stocks Added to Investorideas.com

Energy, Mining, Biotech, Sports and Automotive Stocks Added to Investorideas.com

New Energy Stocks Added to Directory - $DEN.TO, $EGL.TO, $EW.V, $ENG.V, $EEL.V and $FEN.V

Point Roberts, WA, Delta BC – April 13, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in energy, mining, biotech, sports and automotive.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The newest additions to the energy stocks directories are all TSX and TSX Venture listed companies engaged in oil and/or oil and gas exploration.  These companies operate in North America, Oceania, Africa, Europe and New Zealand.

The latest additions to the mining sector are TSX and ASX (Australia) listed companies operating in the exploration and production of zinc, gold and potash with operations in North, South and Central America and Ireland and include one company crossing over into the agriculture sector - Aguia Resources Limited (ASX:AGR.AX), a fertilizer company that is mining, exploring and developing  phosphate and potash projects in Brazil.

Biotech additions are both Nasdaq-listed and include a company working with treatment for diabetes as well as a company developing oncology therapeutics.

Finally, the sports sector has been updated with Netshoes (Cayman) Limited (NYSE: NETS), a Latin American sporting goods retailer and Sport Endurance, Inc. (OTCQB:SENZ), a manufacturer of nutritional supplement products. The automotive sector has added the TSX-Listed Xpel Technologies (TSX: DAP-U.V) a leading supplier of automotive paint, headlamp and window protection films.

   

New Energy Companies Added to Investorideas directory:

Dundee Energy Limited (TSX:DEN.TO) is a Canadian-based oil and natural gas company with a mandate to create long-term value for its shareholders through the exploration, development, production and marketing of oil and natural gas, and through other high impact energy projects. Dundee Energy holds interests, both directly and indirectly, in the largest accumulation of producing oil and gas assets in Ontario and, through a preferred share investment, in certain exploration and evaluation programs for oil and natural gas offshore Tunisia.

Eagle Energy Inc. (TSX:EGL.TO) owns stable, primarily oil producing properties with development and exploitation potential in Canada and the United States. Eagle operates all four of its major assets.

East West Petroleum (TSX:EW.V) is a company established in 2010 to invest in international oil & gas opportunities. East West has built a diverse portfolio of attractive exploration assets covering a gross area of over one million acres. The Company has its primary focus on two key areas: New Zealand, where it has established production and cash flow and is evaluating a low risk exploration play, and Romania where it is fully carried on a seismic surveying and 12 well exploration program. In New Zealand, East West holds an interest in three exploration permits near to existing commercial production in the Taranaki Basin, operated by TAG Oil Ltd. The Company also has interests in four exploration concessions covering 1,000,000 acres in the prolific Pannonian Basin of western Romania with Naftna Industrija Srbije ("NIS").

Energulf Resources Inc. (TSX:ENG.V) is a publicly traded international oil and gas exploration company focused on maximizing shareholder value by targeting high impact opportunities that present explosive growth potential for shareholders. EnerGulf Resources Inc. is a Toronto, Canada based oil and gas exploration company. It also has offices in Kinshasa, Democratic Republic of Congo. EnerGulf’s subsidiaries are EnerGulf Corporation, EnerGulf Africa Ltd., EnerGulf Namibia Ltd., EnerGulf DRC, Ltd. and EnerGulf Congo, SARL.

Esrey Energy Ltd. (TSX:EEL.V) (formerly LNG Energy Ltd.) is a Canadian petroleum exploration and development company focused on developing oil and gas reserves in Papua New Guinea and Bulgaria.

Forent Energy Ltd. (TSX:FEN.V) is a Calgary-based junior oil and natural gas producer focused on near-term growth through asset acquisitions, infill development drilling of oil producing properties in Southern Alberta and exploration drilling for high impact, multi-zone oil and gas potential at Montgomery, Alberta. Forent is well positioned for growth as it has an experienced, technically based management team, strong board of directors, sustainable production base and manageable debt.

New Mining Companies Added:

Adventus Zinc Corporation (TSX:ADZN.V) is a newly formed company focused on zinc exploration in Ireland and Eastern Canada, as well as pursuing the acquisition of advanced zinc projects. Its major shareholders are experienced and respected investors in the mining business, providing significant financial and technical support.

Aguia Resources Limited (ASX:AGR.AX) a fertilizer company, mines, explores, and develops phosphate and potash projects in Brazil. Its flagship Rio Grande phosphate assets include the Três Estradas, Joca Tavares, Porteira carbonatite, and Cerro Preto deposits, which cover an area of approximately 78,150 hectares located in the state of Rio Grande do Sul in southern Brazil..

                             

Alicanto Mining Corp. (ASX:AQI.AX) is an ASX listed mineral exploration Company focused on the exploration and development of a portfolio of gold projects in the prospective geological province of the Guiana Shield in South America. In addition to the exploration of its current Guyanese projects, the Company is continuously evaluating additional projects in both Guyana and overseas for potential joint venture or acquisition.

Anconia Resources Corp. (TSX:ARA.V) is a base and precious metals exploration and development company, which is focused on providing shareholder value through the advancement of its properties in its portfolio. Anconia is undertaking comprehensive exploration programs to determine the potential of its current projects.

Ascendant Resources Inc. (TSX:ASND.V) (formerly known as Morumbi Resources Inc.) is a mining issuer focused on its flagship operating asset, the producing El Mochito zinc, silver and lead mine in west-central Honduras in which the Company has a 100% interest. El Mochito has been in almost continuous production since 1948. More broadly, the Company evaluates producing and advanced development stage mineral resource acquisition opportunities in North, South and Central America, on an ongoing basis.

New Biotech Companies Added:

Valeritas Holdings, Inc. (NasdaqCM:VLRX) is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts.

Xenetic Biosciences Inc. (NasdaqCM: XBIO) is a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's proprietary drug development platforms include PolyXen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. Xenetic's lead investigational product candidates include oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer (EC), and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also working together with Shire plc (formerly Baxalta, Baxter Incorporated and Baxter Healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on Xenetic's PolyXen technology to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is a significant stockholder of the Company, having invested $10 million in the Company during 2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Shire's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100 million plus royalties on sales. Additionally, Xenetic has previously received strategic investments from OPKO Health (OPK), Serum Institute of India Limited and Pharmsynthez. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications.

New Sports Companies Added:

Netshoes (Cayman) Limited (NYSE: NETS) is the leading sports and lifestyle online retailer in Latin America and one of the largest online retailers in the region, with operations in Brazil, Argentina, and Mexico. Through the websites Netshoes and Zattini, as well as through partner-branded store sites it manages, Netshoes offers customers a wide selection of products and services for sports, fashion and beauty. Netshoes recently started to provide B2B operations to partner suppliers, and launched its online third-party marketplace across all of its sites.

Sport Endurance, Inc. (OTCQB:SENZ) develops, markets, and distributes nutritional supplement products throughout the United States. We believe improved health contributes to and promotes a higher quality of life. It’s our goal to improve health by providing quality and effective nutritional supplements. Our primary focus is on three areas of health that most directly impact the lives of most active adults – Total Wellness, Performance, and Recovery.

New Automotive Companies Added:

Xpel Technologies (TSX: DAP-U.V) is the leading supplier of automotive paint, headlamp and window protection films with over 70,000 vehicle-specific applications and a worldwide network of trained installers. Using XPEL’s propriety software and patented materials, our professional design team develops products that deliver the ultimate in vehicle protection, meeting the demands of a broad range of makes and models. XPEL is the developer of the Design Access Program software, and manufacturer of XPEL™ Automotive Paint and Headlamp Protection Products. XPEL has forged the cutting-edge of automotive protection technology, and leads the industry in quality, technical support and customer service.

Read this release in full at http://www.investorideas.com/news/2017/main/04131Stocks.asp

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Canadian Cannabis Stock News: Aphria (TSX: $APH) (OTCQB: $APHQF) Records fifth consecutive quarter of profitability

 

Increases capacity expectations for Part II, III & IV expansion projects to meet growing demand

LEAMINGTON, ONTARIO - April 13, 2017 (Investorideas.com Newswire) Aphria Inc. ("Aphria" or the "Company") (TSX:APH)(OTCQB:APHQF) today reported its third quarter results, for the three and nine months ended February 28, 2017. All amounts are expressed in Canadian dollars.

Business highlights

• Fifth consecutive quarter of profitability
• Over $3.2 million of year-to-date EBITDA
• Increased our capacity expectations for Part II (to 8,000 kgs), Part III (to 22,000 kgs) & to Part IV (75,000 kgs)
• Invested $1,000,000 in Resolve Digital Health Inc.
• Invested $1,000,000 in Tetra Bio-Pharma Inc., which was subsequently increased to $2,300,000 after exercising warrants in the subsequent events period
• Secured 200 acres of serviced farm land in Leamington, Ontario for $6,240,000 as a secondary site to our existing campus
• Invested an additional $1,300,000 USD in Copperstate Farms Investors, LLC, which was subsequently increased by a further $3,000,000 USD investment in the subsequent events period
• Invested $8,400,000 in Canabo Medical Inc.
• Received Board approval to commence Part IV expansion with a $137,000,000 capital budget
• Committed $2,000,000 in investment to Green Acres Capital Fund, advancing $300,000
• Invested just over $2,000,000 in Kalytera Therapeutics Ltd.
• Raised $53,869,357 in a bought deal financing which closed on February 24, 2017
• Received final approval to list on the Toronto Stock Exchange ("TSX"). Shares commenced trading on the TSX and were delisted from the TSX-Venture Exchange on March 22, 2017

"With five consecutive quarters of profitability and further growth in our production capacity, Aphria continued to build strong, positive momentum in the third quarter," said Vic Neufeld, Chief Executive Officer, Aphria. "Despite unusual weather conditions that temporarily added to our growing costs for the quarter, we continue to report costs per gram that are among the lowest in the industry. At the same time, we are making strategic investments that will increase our supply of high-quality cannabis and position Aphria to drive further growth in our medical-grade cannabis business, meet future demand for recreational cannabis, and drive strong, sustainable shareholder value creation."

Financial highlights

For the fifth consecutive quarter, the Company reported profitability. In the last five quarters, the Company reported income before tax of $3,720, $102,164, $895,269, $945,678 and $4,950,250, respectively. The increased pre-tax profitability is primarily a result of the increase in fair value of long-term investment portfolio.

The Company continued to report strong EBITDA levels, reporting $1,005,073 of EBITDA in the quarter. This is the Company's third consecutive quarter with EBITDA greater than $1 million. Reported EBITDA levels reflect the Company's continued focus on low cost producer status and industry leading patient care service.

Revenue for the three months ended February 28, 2017 was $5,118,516, representing a 2% decrease over the prior quarter's revenue of $5,226,589. The decrease in revenue for the quarter was consistent with expectations and was primarily a result of the $8.50 per gram cap placed on the price of medical cannabis for veterans. The impact of the price cap on revenue was offset by increased revenue per gram for non-veterans, primarly a result of selling less wholesale product and the continued growth of our cannabis oils.

Adjusted gross profit for the third quarter was $3,582,312 with an adjusted gross margin of 70.0%, generated from both retail and wholesale shipments of medical cannabis. The decrease in the adjusted gross margin from the prior quarter is consistent with the reduction in revenues in the quarter.

During the quarter, our "all-in" costs of dried cannabis per gram increased from $1.79 in the prior quarter to $2.23 in the current quarter, representing a $0.44 increase. The increase largely related to abnormal winter weather conditions in Leamington but also included costs related to preparing for our Part II expansion.

This winter the Leamington area experienced unusual conditions related to the amount of sunlight it received. The most common measure of light intensity is referred to as lumens. During the quarter, the Leamington area received approximately 80% of the historical three-year average of lumens for this period. More specifically, the month of January was 67% of the three-year lumen average and the month of February was 76% of the three-year lumen average. This reduced lumen measure directly led to (i) lower yields on individual cannabis plants during the quarter which caused a $0.20 increase in our "all-in" costs of dried cannabis per gram; and, (ii) increased heating and electrical costs, which caused a $0.14 increase in our "all-in" costs of dried cannabis per gram.

The remaining $0.10 per gram related to incremental labour costs as we added greenhouse staff during the quarter so they would be fully trained to work in our Part II expansion, the moment the area is approved by Health Canada. As we move from Health Canada's approval to use our Part II expansion toward the first sale from that area, we will continue to incur incremental labour costs in our vault and packaging staff. These incremental costs will be directly tied to revised head counts as we properly train staff in advance of additional product flow that will result from the increase in our annual harvest from 2,600 kgs to 8,000 kgs.

Net income for the three months ended February 28, 2017 was $4,950,250 or $0.04 per share as opposed to a net income of $3,720 or $0.00 per share in the same quarter in the previous year and an income before tax of $945,678 or $0.01 per share in the previous quarter.

EBITDA for the third quarter was $1,005,516, compared to an EBITDA of $423,350 in the same period of the prior year and EBITDA of $1,198,620 in the previous quarter.

We have A Good Thing Growing.

Read this release in full at http://www.investorideas.com/420cannabisinvestorideas/Companies/APH/news/2017/04131Profitability.asp

About Aphria

Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.

For more information, visit www.Aphria.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations for future growing capacity and costs, the completion of any capital project or expansions, any commentary related to the legalization of marijuana and the timing related thereto, expectations of Health Canada approvals and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contact Information

Vic Neufeld
President & CEO
1-844-427-4742

Disclosure: Aphria Inc. (TSX:APH) (OTCQB:APHQF) is a featured company on the 420 Cannabis Investor Ideas of 2017 at www.420cannabisinvestorideas.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: Companies Featured on the 420 Cannabis Investor Ideas have paid a one-time fee of Up to $1000 to be featured on the directory

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Defense Stock News: Patriot One (TSX.V: $PAT) (OTCQB: $PTOTF) Announces Canadian Research Partnership Grant to Advance Concealed Weapons Detection PATSCAN™ 2.0

Defense Stock News:  Patriot One (TSX.V:  $PAT) (OTCQB:  $PTOTF) Announces Canadian Research Partnership Grant to Advance Concealed Weapons Detection PATSCAN™ 2.0

NSERC’s Idea to Innovation grant supports technological evolution

TORONTO, ON– April 13, 2017) – (Investorideas.com Newswire) Patriot One Technologies Inc., (TSX.V: PAT) (OTCQB: PTOTF)   (FRANKFURT: 0PL) (“Patriot One” or the “Company”), developer of a revolutionary concealed weapons detection system, advises today that its university research partner was awarded CAD$161,321 from the Natural Sciences and Engineering Research Council’s (NSERC) Idea to Innovation Phase II Grant, which will help to advance and further evolve its Intellectual Property (IP) portfolio.

NSERC’s grant, along with cash and in-kind contributions from Patriot One, creating a total project value of almost CAD$355,000, will assist in propelling the Company towards new products and solutions for the detection of concealed weapons. Proposed advances include practical trials aimed at commercial development of low power wearable and vehicle mounted adaptations of its innovative software and related hardware solution.

News of the funding comes at a time of growing public interest as the Company recently received significant industry recognition of its efforts as category winners (Anti-Terrorism & Force Protection) at the 2017 Security Industry Association’s (SIA) New Product Showcase (NPS) component of the ISC West conference and trade show, the largest annual industry event of its kind in North America.

Patriot One CTO, Dinesh Kandanchatha notes, “Even as we bring our initial product to market, our strategic long term planning actually began some time ago when we began discussions to look at alternative threats and ways of addressing those needs through product adaptation. Todays announcement brings us that much closer to delivering our latest technology 2.0 platform, what we are calling PATSCAN™, the next generation of our award-winning Patriot One NForce CMR1000 software and radar solution. We thank NSERC and our partners for making today’s funding announcement possible and look forward to continued success as we move forward with new and exciting advancements to our technology.”

ON BEHALF OF THE BOARD

“Martin Cronin"
President & Director

Read this release in full at http://www.investorideas.com/news/2017/defense/04131PatriotOne.asp

About Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB: PTOTF) (FRA: 0PL):

Patriot One has developed a first-of-its-kind Cognitive Microwave Radar concealed weapons detection system as an effective tool to combat active shooter threats before they occur. Designed for cost-effective deployment in weapon-restricted buildings and facilities, the innovative software solution and related hardware can be installed in hallways and doorways to covertly identify weapons and to alert security of an active threat entering the premises. Owner/operators of private and certain public facilities can now prominently post anti-weapons policies with compliance assured. The Company’s motto Deter, Detect and Defend is based on the belief that widespread use of its technology will act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the globe. For more information, visit: www.patriot1tech.com.

For further information, please contact:

Patriot One Inquiries

+1 (888) 728-1832

info@patriot1tech.com

www.patriot1tech.com

CAUTIONARY DISCLAIMER STATEMENT:

No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news is published on the Investorideas.com Newswire – News that Inspires big ideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure this news is a paid for news release on the Investorideas.com newswire by Patriot One Technologies Inc., (TSX.V: PAT) (OTCQB: PTOTF)  Learn more about costs and our newswire service http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

HomelandDefenseStocks.com - investing ideas for Defense stocks, Biometrics stocks, Homeland security stocks, Biodefense stocks, Cyber security stocks

Like Defense and Security Stocks? View our Defense and Security Stocks Directory  Get News Alerts on Defense Stocks